Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic versus CellCept for gastrointestinal symptoms after kidney transplant
2005-004024-39Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Kidney allograft status (RTx) comparing Myfortic switch arm with CellCept standard treatment arm (2 arms). Primary endpoint: Change in GIQLI total score. Started Mar 2006; status: completed.
02
Drugs
mycophenolate sodiummycophenolate mofetil
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2005-004024-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004024-39.